NSD3 and cancer: The nuclear receptor-binding SET domain (NSD), a family of histone lysine methyltransferases, including NSD1, NSD2/WHSC1/MMSET, and NSD3/WHSC1L1, have been identified as potential therapeutic targets for cancer [5].